Supriya Lifescience shares plummeted 10.24% to ₹879.25 as of 14:46 IST on July 6, 2026, making it the biggest loser in the BSE's 'A' group. The stock witnessed significantly higher trading volumes with 1.01 lakh shares traded compared to the average daily volumes of 18,154 shares in the past month. According to Business Standard, this represents a substantial increase in trading activity amid the ongoing legal proceedings. The stock had previously experienced a 12% plunge on June 2, 2026, and hit a 52-week high of ₹1,085.50 on June 1, 2026, demonstrating the volatility in recent trading sessions.
According to Business Standard and earlier reports from CNBC TV18 and TipRanks, Supriya Lifescience Ltd. announced that the Special Investigation and Intelligence branch of the Customs Department has initiated a probe against its general manager, sales and marketing officer Sreekant Sreedharan. The proceedings were initiated on July 3, 2026 and have been placed under judicial custody until July 17, 2026. The investigation has been initiated under the Narcotic Drugs and Psychotropic Substances (NDPS) Act, 1985 for a procedural lapse related to a single export transaction of an identified product. As per the latest company disclosure, the proceedings were initiated against the personnel of the company under the NDPS Act, 1985 for a procedural lapse for a single export transaction of an identified producer.
According to the company's latest disclosure, the investigation was initiated on July 3, 2026 and judicial custody has been granted by the Chief Metropolitan Magistrate (CMM) court till July 17, 2026. The company emphasized that the proceedings are not expected to have any material impact on its operations, financial position or governance. Supriya Life stated it is evaluating the implications of the proceedings and is obtaining appropriate legal advice, as reported by Business Standard. The company added that the matter is before the competent court, and the company will take an appropriate action after examining all applicable legal provisions and implications.
As reported by Business Standard, the company stated that the matter pertains to the concerned employee and, based on the information currently available, is not expected to have any material impact on the company's operations, financial position or corporate governance. Supriya Life reaffirmed its commitment to maintaining the highest standards of corporate governance and regulatory compliance. The company added that it is closely monitoring the developments in the case and any further material developments will be disclosed to the stock exchanges in accordance with applicable laws and regulations. The company's management emphasized that their focus remains on expanding the regulated market while strengthening competitive edge through backward integration and regulatory expertise.
According to Business Standard, Supriya Lifescience is a Mumbai-based manufacturer of active pharmaceutical ingredients with a presence in more than 120 countries. The company serves therapeutic segments including antihistamines, anti-allergics, vitamins, anaesthetics and anti-asthmatics. In its latest quarterly results, the company reported consolidated net profit of ₹74.23 crore in Q4 FY26, representing a 47.4% YoY and 49.4% QoQ increase. Revenue from operations jumped 50.2% YoY and 34% QoQ to ₹276.53 crore in the March 2026 quarter. Looking ahead, analysts at Choice Institutional Equities expect the company's revenue to see exponential year-on-year growth in Q1FY27 due to a low base last year, with sequential growth expected in high single digits. The brokerage firm believes the company's leadership in niche therapies and strong backward integration capabilities should support margin expansion from FY28E.
